Evazarsen clinical trials
Also written ISIS 757456.
Includes 3 studies of Evazarsen sodium.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses evazarsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ISIS 757456
- 2
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses evazarsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood PressureCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT04714320Written as IONIS-AGT-LRxHow we know
- A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection FractionCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT04836182Written as IONIS-AGT-LRxHow we know
- A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRxCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT04083222Written as ISIS 757456How we know
- A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood PressureCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT03714776Written as ISIS 757456How we know
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy VolunteersCompletedPhase 1Ionis Pharmaceuticals, Inc.NCT03101878Written as Ionis AGT-LRxHow we know
Codes
What other systems call evazarsen · ClinicalTrials.gg INT017516
- UNII (FDA) P048YHG804EVAZARSENOne source FDA
- NCI Thesaurus C188610EvazarsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P048YHG804 | EVAZARSEN | One source FDA |
| NCI Thesaurus | C188610 | Evazarsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.